The recent review article entitled "Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors " by Ute F. Röhrig et al. depicts inhibitors for IDO1; among them natural products. The following text lists some references for those studies on natural products:
Natural-product-derived IDO1 inhibitors were frequently isolated from marine organisms.19,91,99,113−126 While providing good starting points in general for the development of new therapeutics, they also feature some drawbacks. The typical
complexity and large molecular weight of natural products make it often difficult to derive drug like compounds. In the case of IDO1, a large number of natural product inhibitors contains problematic functional groups such as quinones. Frequently, only enzymatic assay results for one or a few compounds were reported, hindering the evaluation of their potential usefulness.
For getting the full references (19,91,99,113−126) please see attached review article named "Enz 1).
Another interesting review on this topic is the one by Platten et al. entitled " Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors" published in Front. Immunol., 12 January 2015 | http://dx.doi.org/10.3389/fimmu.2014.00673.